The inflammasome in atherosclerosis and type 2 diabetes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21543720.
- Also identified by DOI 10.1126/scitranslmed.3001902.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Atherosclerosis is the cause of morbiditiy for 70% of patients with type 2 diabetes. In both of these diseases, a protein complex known as the inflammasome is stimulated to activate interleukin-1β (IL-1β) and IL-18, which are pathogenic inflammatory cytokines. Triggers for the inflammasome are obesity-related factors, such as cholesterol crystals in atherosclerosis, or hyperglycemia, ceramides, and islet amyloid polypeptide in type 2 diabetes. Therapeutics that target IL-1β in clinical trials for type 2 diabetes might also decrease the incidence of atherosclerosis.
Medical subject headings
- Atherosclerosis
- Diabetes Mellitus, Type 2
- Inflammasomes